Bora Biologics Expands Through Acquisition and Partnership

Bora Biologics has recently made a series of strategic moves aimed at better positioning itself to rapidly respond to industry’s evolving demands for capacity, integration, and policy developments - such as the U.S. BIOSECURE Act. As a result, the company is well positioned to capitalize on the growing demand for large-molecule CDMO services and opportunities presented by the growing demand for onshoring and friendshoring.

Bora recently announced the completion of a deal to acquire Emergent BioSolutions’ sterile manufacturing facility in Baltimore, Maryland, allowing the Bora Group to integrate ‘drug product’ supply with its existing drug substance business; an essential for CDMOs offering services for large molecule programs.

Soon after, the group announced a strategic investment in Tanvex Biopharma – adding the company’s biologics development and manufacturing operations in San Diego and Taiwan, to combine with Bora’s wholly owned Bora Biologics subsidiary. As a result, more than 100,000 sq. ft. of biomanufacturing space and 1,000-liter bioreactors were added to Bora’s existing 500-liter bioreactors and position the company to better provide customers with a scalable drug substance offering. Initiated by Bora, Tanvex announced it would appoint industry veteran Stephen Lam as the company’s CEO, who boasts more than 35 years’ experience in biopharma, including roles at Lonza, Amgen and Patheon.

These strategic moves followed closely on the heels of Bora’s acquisition of Upsher Smith’s extensive small molecule operations, demonstrating the group’s continued ambitions to expand its small-molecule CDMO services, and its U.S.-based offerings.